What is Omnipod?
What Is Omnipod®?
Discover simplified diabetes management with Omnipod, a tubeless insulin delivery system designed for people with type 1 diabetes.
The Omnipod, Omnipod DASH® and Omnipod® 5 systems offer customisable continuous insulin delivery through a wearable and waterproof‡ patch pump, called a Pod.
With no multiple daily injections to interrupt your day, and no tubes to cause unwanted tangles, it’s time to discover the freedom of Pod Therapy.
How Omnipod Works
Tubeless: Forget the tubes of traditional insulin pumps.
Wearable: Place the Pod almost anywhere you’d normally inject insulin.
Waterproof‡: Wear your Pod in the shower, swimming pool or sea!
Each wearable Pod gives you up to three days (72 hours) of continuous insulin delivery, avoiding the inconvenience and interruptions of up to 14 injections* per Pod.
You’re in control with personalised insulin doses, delivered in just a few finger taps via the Pod’s handheld companion, while the built-in Bolus Calculator takes the headache out of mealtime maths.
Simplify diabetes management with Omnipod!
*Chiang et al. Diabetes Care. 2014:37:2034-2054. 14 injections/3 days based on people with T1D on MDI taking ≥ 3 bolus and 1-2 basal injections/day multiplied by 3 days.
Unlock the Power of Pod Therapy
Meet our tubeless, wearable Omnipod lineup
Discover Omnipod® 5
Omnipod 5 is now compatible with Dexcom G7 sensor, as well as Dexcom G6 sensor and Freestyle Libre 2 Plus sensor (launch timings might differ between sensors compatibility)! It’s the first and only tubeless automated insulin delivery (AID) system that works with the leading sensor brands*.
Omnipod 5 makes automated† insulin adjustments every five minutes based on continuous glucose monitor (CGM) readings, to improve time in range while lowering HbA1c1,2. With a choice of sensor integration, you can experience the freedom of AID without switching from your preferred sensor.
And there’s so much more to Omnipod 5 that can help you to level up your life!
- SmartAdjust™ technology automatically increases, decreases, or pauses insulin every five minutes based on your customised Target Glucose —helping to protect against highs and lows, day and night1,2. Share the load with the system that never sleeps.
- Activity feature helps you to sweat without the stress. When enabled, Activity Mode reduces insulin delivery when glucose typically goes low, for example when exercising.
- SmartBolus Calculator is the first AID system with a SmartBolus calculator, informed with sensor value and trend, so you don’t have to do the maths.
Say hello to Omnipod DASH®
Simplify Life™ with Omnipod DASH. Place the Pod on your body almost anywhere you would inject insulin for up to three days (72 hours) of continuous insulin delivery.
The Personal Diabetes Manager (PDM) communicates wirelessly with the Pod, so you can adjust your insulin doses discreetly and easily wherever you are, without the need for tubing.
Say yes to life with Omnipod DASH and discover life, uninterrupted!
Looking for more information
Check out our library of resources to continue learning about Omnipod:
*[Requires Dexcom G6, Dexcom G7 or FreeStyle Libre 2 Plus sensor. Bolus for meals and corrections are still needed. A separate prescription is required for the sensor. The Dexcom G6, Dexcom G7 and FreeStyle Libre 2 Plus sensors are sold separately.]
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, P<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), P<0.0001. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.1% vs. 20.7%; 42.2% vs 20.7%, P<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.6% vs. 26.1%; 46.4% vs 33.4%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 3.64% vs. 1.17%, P<0.0001; 2.51% vs. 1.78, P=0.0456, respectively. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.64% vs. 1.37%, P<0.0001; 2.13% vs. 1.98%, P=0.2545, respectively.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (P<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 38.4% vs. 16.9%, P<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.7% vs. 33.7%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.41% vs. 2.13%, P=0.0185. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.44% vs. 2.57%, P=0.0799.
3. The Omnipod 5 System was named 2023 Patient Choice Award Winner for preferred pump in the United States; Source: Seagrove Patient Perspectives Survey Report (413 Total Responses, 260 T1D, 153 T2D - 245 pumpers, 98 MDI, 70 non-MDI). Seagrove Partners, LLC Patient Perspectives Report, December 2023. Insulet data on file.